Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/2/2024 | $17.00 | Outperform | Oppenheimer |
| 6/14/2024 | $15.00 | Buy | Maxim Group |
| 6/13/2024 | $10.00 | Buy | Rodman & Renshaw |
| 4/17/2023 | $24.00 | Buy | BTIG Research |
| 10/11/2022 | $15.00 | Buy | UBS |
| 7/27/2022 | $22.00 | Buy | H.C. Wainwright |
| 6/13/2022 | $28.00 | Outperform | Wedbush |
| 8/25/2021 | $24.00 | Buy | BTIG |
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting transenteric delivery of GLP-1 incretin triagonist - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 - SAN JOSE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter ended September 30, 2024 and provided a corpor
SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company's management team will participate in three upcoming conferences. These conferences include: UBS Global Healthcare Conference Location: Terranea Resort, Rancho Palos Verdes, CADate: Thursday, November 14, 2024 at 10:15am PTFormat: Fireside Chat and 1x1 Meetings Stifel Healthcare Conference Location: Lotte New York Palace Hotel, New York, NYDate: Monday, November 18, 2024 at 4:10pm ET Format: Fireside Chat and 1x1 Meetings 7th
-Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and bioavailability comparable to subcutaneous injection - - New pharmacokinetic data provides further evidence of the RaniPill platform's potential to enable oral delivery of multiple obesity treatments - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 - SAN JOSE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics an
Oppenheimer initiated coverage of Rani Therapeutics with a rating of Outperform and set a new price target of $17.00
Maxim Group initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $15.00
Rodman & Renshaw initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $10.00
- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 - Presentation of late-breaking abstract on oral delivery of GLP-1 agonist at American Diabetes Association's Scientific Sessions - Plan to initiate Phase 2 study for RT-102 and Phase 1 study for RT-111 in 2H of 2023 SAN JOSE, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings,
SAN JOSE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has appointed Kate McKinley as its Chief Business Officer. "Kate is a seasoned industry leader, and we are thrilled to welcome her to Rani's executive team," said Talat Imran, Chief Executive Officer of Rani. "Kate's expertise in corporate strategy, business development and commercialization will further strengthen our leadership team and partnering efforts, while positioning the Company for its next stage of growth. Kate will have a vital role
- Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis – - Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of up to 20 mg – - Strengthened Board with the appointment of Lisa Rometty - SAN JOSE, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. "We started the year off strong, having unveiled the high-capacity RaniPill HC, advanced RT-102 into the clinic for a Phase 1 trial in o
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $13 price target.
Under the terms of the collaboration agreement, Rani and ProGen agree to share responsibilities for the development and commercialization of RT-114 worldwide, including a 50/50 cost and revenue share arrangement. Rani has exclusive rights to lead development and commercialization of RT-114 in the United States, Europe, Canada and Australia, and ProGen has exclusive rights to lead development and commercialization in the rest of the world. Each party has certain rights to sublicense in its territories. Rani is designated to lead operationally in conducting preclinical and development activities through the Phase 1 program, which is expected to initiate in 2025. As part of this agreement, ther
~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and ProGen to share responsibilities for the development and commercialization of RT-114, including a 50/50 cost and revenue share arrangement ~ ~ Rani to host conference call today at 8:00 a.m. ET/5:00 a.m. PT ~ SAN JOSE, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani")(NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist - - Cash runway extended into 2025 - - Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT - SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update. "
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 20, 2024. Individuals interested in listening t
10-Q - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
8-K - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
8-K - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
SC 13G - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
SC 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
SC 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)